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In ostriches, the population densities resulting from intensive rearing increases
susceptibility to pathogens such as mycoplasmas. In addition to good management
practices, vaccination offers an attractive alternative for controlling mycoplasma
infections in food animals, instead of using antibiotics, which often leave unacceptable
residues. The use of live attenuated vaccines, however, carry the concern of reversion to
virulence or genetic recombination with field strains. Currently there are no commercially
available vaccines against ostrich-infecting mycoplasmas and this study therefore set
out to develop and evaluate the use of a DNA vaccine against mycoplasma infections in
ostriches using an OppA protein as antigen. To this end, the oppA gene of “Mycoplasma
nasistruthionis sp. nov.” str. Ms03 was cloned into two DNA vaccine expression vectors
after codon correction by site-directed mutagenesis. Three-months-old ostriches were
then vaccinated intramuscularly at different doses followed by a booster vaccination
after 6 weeks. The ability of the DNA vaccines to elicit an anti-OppA antibody response
was evaluated by ELISA using the recombinant OppA protein of Ms03 as coating
antigen. A statistically significant anti-OppA antibody response could be detected after
administration of a booster vaccination indicating that the OppA protein was successfully
immunogenic. The responses were also both dose and vector dependent. In conclusion,
the DNA vaccines were able to elicit an immune response in ostriches and can therefore
be viewed as an option for the development of vaccines against mycoplasma infections.
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INTRODUCTION
The ostrich (Struthio camelus var. domesticus) is the largest living, flightless bird species belonging
to the ratite group (1). Although ostriches are traditionally endemic to Africa, parts of Arabia and
the Middle East (2), they are reared in several countries across the world. South Africa, however,
is currently the largest producer of ostrich products (meat, leather, and feathers) on international
markets (3). Here, the majority of ostriches destined for slaughter are reared in free-range systems,
but when environmental conditions are unfavorable for grazing, they are reared in grow-out
camps from about 3 months of age (4). Mycoplasma, a genus of bacteria that belongs to the
prokaryotic class Mollicutes, is known to be highly infectious in these intensive rearing systems
(5, 6). Characteristic features of mycoplasma include the lack of a cell wall, small AT-rich genome
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and a minimal set of genes (7, 8). The species found to
specifically infect ostriches are “Mycoplasma struthionis sp.
nov.” str. Ms01, Mycoplasma sp. str. Ms02, and “Mycoplasma
nasistruthionis sp. nov.” str. Ms03 (9, 10). They are typically
associated with upper respiratory tract infections (9), reduced
growth rates, downgrading of carcasses and in extreme cases,
chick mortalities (5, 9). The severity of infections increases with
exposure to environmentally induced stress, other bacterial and
viral infections. Of the three Mycoplasma species, “Mycoplasma
nasistruthionis sp. nov.” str. Ms03 was found to have the highest
prevalence (6) amongst ostriches and therefore was the focus of
this study.
Mycoplasma infections are currently managed using a
combination of biosecurity systems and antibiotics. With
antibiotics there is the risk of resistance (11) as well as an
accumulation of residues in meat with concomitant risks for
consumers (12). Development of whole organism vaccines for
use in ostriches is limited by the slow-growing nature of these
organisms and the cost of medium required to sustain growth.
DNA vaccines, on the other hand, do not require large scale
cultivation of the pathogen, can be produced at relatively low
cost and are more temperature stable than other vaccines (13,
14). It is therefore an attractive alternative for use in ostriches
where the vaccine market is small, relative to e.g., poultry, and
ostriches are usually farmed in semi-arid or arid regions where
temperatures are frequently high and cold storage of vaccines
can be problematic. Similar to live vaccines, they are also able
to stimulate humoral and cellular immunity as indicated by
measuring antibody, T-helper cell and cytotoxic T-lymphocyte
responses (15). but unlike live vaccines cannot revert back to
an infectious form (16). El Gazzar et al. (17) has reported the
reversion to virulence of a commonly used live mycoplasma
vaccine in poultry, ts-11, whilst another has reported possible
genetic recombination between live vaccines and field strains
upon long term use (18). This exchange or transfer of genes
could have a negative impact on either the pathogenicity or
transmissibility of field strains. Chromosomal integration of
DNA vaccines is of some concern, but preclinical and clinical
studies have shown the rate of integration of plasmid DNA into
the host genome to be lower than that of spontaneous mutations
(19, 20). To date, DNA vaccines have not been tested in ostriches
or any other ratites. The aim of this study was to use the OppA
protein of “M. nasistruthionis sp. nov.” str. Ms03 as antigen in
the development and evaluation of DNA vaccines in ostriches at
different doses and using different vectors.
A DNA vaccine is a plasmid expression vector containing
a gene that codes for a protein antigen. As a result of their
parasitic lifestyle (7), mycoplasmas possess, and rely on, a wide
range of transmembrane transport systems for their survival. The
extracellular components of these transporters are ideal targets
for vaccine development (21, 22). In this study the extracellular
OppA domain of an oligopeptide permease (Opp) transporter
was chosen as protein antigen (23, 24). Using mouse models,
OppA has to date been evaluated as antigen in subunit vaccines
against Brachyspira pilosicoli (25), Moraxella catarrhalis (26),
and Yersinia pestis (27), as well as against Haemophilus parasuis
in pigs (28). OppA has, however, not been evaluated in any
organism as part of a DNA vaccine. In this study we report, for
the first time, that a DNA vaccine can elicit a humoral immune
response in ostriches using OppA as antigen. This response was
both dose and vector dependent.
MATERIALS AND METHODS
DNA Vaccine Development
Site-Directed Mutagenesis of the oppA Gene
Cultures of “M. nasistruthionis sp. nov.” str. Ms03 (GenBank:
KM410300.1) were obtained from Mr J.J. Gouws (Faculty
of Veterinary Science, Onderstepoort, University of Pretoria).
Genomic DNA (gDNA) was isolated from these cultures using
a method described by Hempstead (29). The Type A oppA
gene (24) was amplified from gDNA and cloned into the
pGEM R©-T Easy vector (Promega). Primers used are listed in
Supplementary Table 1 and PCR conditions described in the
Supplementary Procedures. To allow eukaryotic expression of
the oppA gene, it was subjected to site-directed mutagenesis
(SDM) to change 16 mycoplasma tryptophan codons (TGA)
to universal tryptophan codons (TGG). The PCR primers
used for SDM are listed in Supplementary Table 1 and the
SDMprocedure outlined in Supplementary Procedures. Correct
mutation of the gene was confirmed with sequencing by the
Central Analytical Facility, DNA SequencingUnit of Stellenbosch
University using an ABI R© 3100 Genetic Analyser (Applied
Biosystems, USA).
Preparation of DNA Vaccines
pCI-neo (Promega) and VR1020 (Vical Inc.) were chosen
as vaccine vectors (Supplementary Figure 1). The pCI-neo
vector is a mammalian expression vector that contains a
CMV enhancer/promoter region, chimeric intron and SV40
late polyadenylation signal sequence. The VR1020 vector also
contains a CMV enhancer/promoter region, but in combination
with a CMV intron, tissue plasminogen activator (TPA) signal
peptide sequence and a bovine growth hormone polyadenylation
signal sequence. The mutated oppA gene was sub-cloned into
each vector using restriction digestion. For pCI-neo, AccI and
MluI (FastDigest, Thermo Scientific) and for VR1020, BamHI
(Fermentas) restriction enzymes were used according to the
manufacturer’s instructions.
Cultures of the pCI-neo_oppA and VR1020_oppA vaccine
plasmid were prepared and the respective plasmids purified with
an Endotoxin-free plasmid DNA purification kit (NucleoBond R©
Xtra Midi plus EF, Macherey-Nagel, Germany). Yields were
determined using a Nanodrop spectrophotometer. Prior to large
scale plasmid isolation for vaccination, the NucleoBond kit’s
ability to yield supercoiled pCI-neo_oppA and VR1020_oppA
plasmids was evaluated by digesting plasmids with the AccI
and BamHI restriction enzymes, respectively, followed by
electrophoresis on a 1% (w/v) agarose gel. To prepare a sufficient
amount of plasmid for vaccination, the plasmids were prepared
in batches over several days. The purified plasmids were again
evaluated as before to confirm the integrity and supercoiling of
the plasmids prior to being used for vaccination.
Frontiers in Immunology | www.frontiersin.org 2 May 2019 | Volume 10 | Article 1061
Wium et al. DNA Vaccine Against Mycoplasma
The isolated plasmids were diluted to 100, 600, and
1,200µg/ml with sterile PBS (137mMNaCl, 2.7mMKCl, 10mM
Na2HPO4, and 1.5mM KH2PO4, pH 7.2), respectively, a day
before use. Dilutions were prepared under aseptic conditions, in
sterile serum glass bottles, closed with inert silicone stoppers and
sealed with a tear away center aluminum cap (Sigma-Aldrich).
DNA Vaccine Trial
Ethical Approval
Ethical approval was obtained from the Stellenbosch University
Animal Ethics Committee (SU-ACUM 13-00019) as well as the
South African Department of Agriculture, Forestry and Fisheries
(Reference: 12/11/1/1/3) in terms of section 20 of the Animal
Disease Act 1984 (Act No. 35 of 1984).
Animals Used and Trial Location
A group of 140 ostrich chicks of ±3-months-old were randomly
selected from a chick rearing unit in the Fraserburg district
(Northern Cape Province, South Africa). Since Fraserburg is
outside the major commercial ostrich production region, this
limits pathogen exposure during the critical 3–4 months-old
rearing phase (30). As per standard practice, upon reaching a
weight of about 40 kg (±4 months of age), trial ostriches were
transported back (±280 km) to a commercial ostrich farm in
the Oudtshoorn district (Western Cape Province, South Africa).
Three-month-old chicks were chosen for vaccination to allow
sufficient time for a primary immune response to develop
before being transported to a higher stress environment with
concomitant increase in pathogen load and increased risk of
exposure to mycoplasma.
The chicks were quarantined for 28 days after relocation
and random testing was performed for avian influenza. This is
required by avian influenza control measure before ostriches can
be released and allowed to mix with other populations on any
farm to which they have been transported.
At the start of the trial, each ostrich was tagged with a unique
number for identification under the right wing, in accordance
with standard ostrich farming practices. The trial was conducted
under similar conditions to which a commercial vaccine would
be administered and therefore trial ostriches were at all times
housed and treated in the same manner as non-trial ostriches on
the farms. In Fraserburg, the chick rearing units were open air
camps (1,250 m2) with 120–150 chicks per camp. In Oudtshoorn,
ostriches were kept in open air grow-out camps (25,000 m2)
with 100–120 ostriches per camp. The ostriches received food
and water ad libitum and were only handled by trained and
experienced farm personnel. Trial birds were not kept separately
but grouped with other ostriches of the same weight and age.
Vaccination Trial Design
The ostriches were randomly allocated to seven treatment groups
of 20 ostriches each. The pCI-neo_oppA and VR1020_oppA
vaccine groups were vaccinated at a dose of 100, 600, and 1,200
µg, respectively. The last groupwas the control group that did not
receive any vaccine. The dose typically administered to poultry
ranges from 0.25 to 800 µg when injected intramuscularly, with
a booster dose after 2–3 weeks (31–38). Dunham (39) indicated
that larger animals may require a larger dose of 500–2,500 µg,
but that this needs to be optimized for individual vaccines since
the dose required is influenced by the target species, its size and
the efficiency of plasmid delivery. The different doses used in our
study were therefore selected to compensate for the increase in
weight of the ostriches during the course of the trial and the fact
that no adjuvant was used in the vaccine formulation to limit
possible skin reactions which can impact hide quality.
Vaccine doses were administered in a single 1ml volume
at week 0 and a booster injection administered at week 6
by intramuscular injection in the upper thigh. Blood samples
(4ml) were drawn from the jugular vein using 18Gx1/2 ′′needles
(Vacuette R©) and collected in Vacuette R© Z serum sep clot
activator tubes at week 0, 3, 6, and 9. Serum was separated by
centrifugation at low speed for 10min and stored at −20◦C.
Week 0 and 3 samples were collected in Fraserburg, and week
6 and 9 samples in Oudtshoorn. The ostriches were moved from
Fraserburg to Oudtshoorn 12 days prior to the week 6 sampling
and booster injections were therefore administered during the
quarantine period. Ostriches were monitored after vaccination
for any adverse reactions.
Evaluation of Humoral Immune Responses
Expression and Purification of the Recombinant
OppA Protein
For analysis of anti-OppA antibody responses, recombinant
OppA protein was produced for use as coating antigen in an
enzyme-linked immunosorbent assay (ELISA). To this end, the
SDM corrected oppA gene was PCR amplified and sub-cloned
into a pGEX-4T-1 vector (GE Healthcare Life Science, UK) using
restriction digestion. Primer sequences with BamHI and NotI
restriction sites are shown in Supplementary Table 1.
For protein expression, the pGEX-4T-1_oppA plasmid
was transformed into Escherichia coli BL21(DE3)pLysS cells
(Promega) and freezer stocks prepared. An overnight culture
(from a freezer stock) and expression cultures were prepared
using Terrific-Broth (TB) medium. Expression of the glutathione
S-transferase (GST) OppA fusion protein was induced at an
OD600 between 0.4 and 0.6 by the addition of 0.4mM IPTG,
and cells harvested at 0 and 6 h by centrifugation (10,000 ×
g at 4◦C). The cells were resuspended in 1xTen50 extraction
buffer [10mM Tris-HCl, 1mM EDTA, 50mM NaCl, 0.1%
Triton X-100, 0.2M dithiothreitol and 10% glycerol (v/v)] at
100 µl extraction buffer per 1ml culture used for centrifugation.
Protease inhibitor was also added to the Ten50 buffer (1 tablet
per 10ml extraction solution of complete ULTRA Tablets, Mini,
EASYpack tablet, Roche).
The GST-OppA protein was isolated using glutathione-
agarose chromatography (Sigma-Aldrich) under gravity flow at
4◦C according to the manufacturer’s instructions. A sample
(8ml) was prepared for loading of the column by treating the
resuspended pellets with three freeze-thawing cycles (20min
at 37◦C followed by 10min at −80◦C) and five cycles of 2 s
sonication followed by 2min on ice. The samples were then
triturated three times through a 25Gx5/8′′ needle (Avacare) into
a 1ml Injekt-F syringe (BBraun). This was repeated using a
23Gx1/4" needle (Nipro) followed by centrifugation at 10,000× g
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for 10min (4◦C) to obtain a clear supernatant which was loaded
onto the column under gravity flow at 4◦C.
Fractions (1ml) were collected and their protein
concentration determined using a modified Bradford assay
(40). Expression and isolation products were analyzed using
SDS-PAGE (40) and Western blot analysis (41).
Evaluation of Anti-OppA Antibody Response
Microtiter plates (Maxisorp, Nunc) were coated overnight at
4◦C with 100 µl of recombinant GST-OppA protein diluted to
10µg/ml in carbonate buffer (50mM NaHCO3, pH 9.6). To
block non-specific binding, 200 µl/well casein buffer (10mM
Tris-HCl, 154mM NaCl, 0.5% casein and 0.02% Thiomersal,
pH 7.6) was added and the plate incubated for 1 h at 37◦C.
Serum samples were diluted 1:100 with casein-Tween [casein
buffer containing 0.1% (v/v) Tween R© 20] and 100 µl/well
added to the plate in triplicate before incubation for 1 h at
37◦C. Biotinylated rabbit anti-ostrich Ig polyclonal antibodies,
prepared as previously described (42), were next added at a
dilution of 1:100 in casein-Tween and incubated for 1 h at
37◦C. A streptavidin horseradish peroxidase (HRP) conjugate
mixture [2ml Streptavidin HRP (Invitrogen), 38ml 0.5% casein
buffer, and 40ml 50% glycerol], diluted 1:100 with casein-Tween,
was then added (100 µl/well) and the plate incubated for 1 h
at 37◦C. Finally, 100 µl/well substrate solution (0.5 mg/ml
ABTS, 0.5 µl/ml H2O2, 0.1M citrate buffer, pH 5) was added
and absorbance measured at 405 nm with a Thermo Scientific
Multiskan EX plate reader after 30min incubation at 37◦C. After
each incubation step the content of the plate was first decanted
followed by washing five times with PBS-Tween [137mM NaCl,
2.7mM KCl, 10mM Na2HPO4 and 1.5mM KH2PO4, pH 7.2,
0.1% (v/v) Tween R© 20] and washing three times with Milli-
Q R© water. Between the coating and blocking steps washing was
not applied.
A first-row column blank (containing all components except
ostrich serum) was used on each plate to blank absorbance values.
All plates contained controls to monitor plate to plate variation.
The controls were serum samples representing the week 0, 3, 6,
and 9 sampling points of a single ostrich, randomly selected from
the pCI-neo_oppA 1,200 µg group based on high titers produced
after vaccination. Prior to the analysis of samples, the ELISA was
optimized with regard to coating concentration (1–10µg/ml),
serum dilution (1:40–1:640) as well as number of washing cycles
between steps. Non-specific binding of anti-OppA antibodies
during ELISA analysis was evaluated by coating the wells with
carbonate buffer (100 µl/well) containing no capture antigen
and serum from a vaccinated bird that gave a high absorbance
value at a dilution of 1:100 when using the GST-OppA protein as
capture antigen.
The absorbance values obtained are referred to as ELISA titres,
which are a measurement of the antibody levels produced when
using a serum dilution of 1:100 in the ELISA.
Monitoring Weight and
Mycoplasma Infections
The weight of trial birds was monitored and recorded at weeks
0, 6, and 9. To determine the possible influence of existing
mycoplasma infections on immune response data, trachea swabs
were collected at weeks 0, 3, 6, and 9 and tested for the presence
of mycoplasma infections by PCR. Birds were, however, not
excluded from the trial if they tested positive since ostriches are
often naturally infected with mycoplasmas. Swab samples were
collected using dry sterile swabs (Copan) which were then rinsed
in 200 µl sterile PBS buffer. The eluate was tested by PCR using
a generic primer pair specific for the Mycoplasma genus (9).
Positive samples were further evaluated for the presence of the
ostrich-infecting mycoplasmas Ms01, Ms02, and Ms03 (9).
Statistical Analysis of Trial Data
Statistical analysis of the ELISA titer data was performed using
the General Linear Model (GLM) procedure in the Agrobase
Generation II R© (Agronomix Software Inc.) software. Analysis of
variance (ANOVA) and least significant difference (LSD) values
were calculated at a significance level of 0.05.
RESULTS
DNA Vaccine Development
Site-Directed Mutagenesis of the OppA Gene
The 3867 bp oppA gene was successfully amplified from theMs03
gDNA and cloned into a pGEM R©-T Easy vector as confirmed
by sequencing. Using SDM, all 16 mycoplasma TGA codons in
this plasmid were successfully mutated to universal TGG codons
in seven consecutive steps of SDM as confirmed by sequencing
(Supplementary Figure 2).
Preparation of DNA Vaccines
The mutated oppA gene was successfully sub-cloned into the
pCI-neo and VR1020 vaccine vector as confirmed by sequencing
(Supplementary Figure 2). Large scale production of the DNA
vaccines was achieved and approximately 89mg of plasmid
was isolated for each of pCI-neo_oppA and VR1020_oppA.
The 260/280 absorbance ratio of the isolated plasmids ranged
from 1.89 to 1.95. The integrity of the isolated plasmids was
confirmed with agarose electrophoresis and most of the pDNA
was in the required supercoiled conformation. A supercoiled
conformation has a higher transfection rate into mammalian
cells, is less susceptible to intracellular degradation and is more
effective at inducing an immune response than other plasmid
conformations (43, 44).
DNA Vaccine Trial
Ostriches were vaccinated with the prepared DNA vaccines and
no adverse reactions were observed at the injection sites (redness,
swelling, inflammation, or allergic reaction) during and after
the trial. Ostriches resumed normal behavior such as eating,
walking around and exploring immediately after vaccination (no
lameness or loss of appetite).
Evaluation of Humoral Immune Responses
Expression and Purification of the Recombinant
OppA Protein
Sub-cloning of the mutated oppA gene into the pGEX-
4T-1 vector was successful as confirmed by sequencing
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(Supplementary Figure 2). SDS-PAGE and western blot analyses
confirmed that the recombinant OppA protein was expressed
successfully as an N-terminal GST-fusion protein with the
predicted size of 170 kDa (26 kDa due to the GST tag)
(Figures 1A,B). Bradford analysis indicated that the OppA
protein was eluted between fraction 7 and 12 with the highest
concentration obtained in the 9th fraction.
Evaluation of Anti-OppA Antibody Response
Ostriches with more than two missing sampling points were
excluded from ELISA and subsequent statistical analysis. There
was no non-specific binding of the anti-OppA antibodies in
ostrich serum and the plate control samples indicated limited
plate to plate variation.
The titer values resulting from vaccination with the
pCI-neo_oppA and VR1020_oppA vaccines are shown in
Figures 2A,B, respectively. The titer values of the control group,
which received no vaccine, did not show significant variation
over time. However, there was a slight increase in the average
titer at week 9. Vaccination with the pCI-neo_oppA vaccine
(Figure 2A) resulted in significant treatment x time interactions
(P = 0.0462), but only the 100 and 600 µg doses resulted
in average ELISA titers that differed significantly from the
control. This was also only at week 9 after a booster vaccination
was administered. The average titers of the different doses
were, however, not significantly different from one another.
Vaccination with the VR1020_oppA vaccine (Figure 2B)
resulted in a significant treatment × time interaction (P <
0.001) and all three doses resulted in average ELISA titers
that differed significantly (LSD = 0.2796) from the control.
This was again only at week 9 after a booster vaccination




The vaccinated groups as well as the control group gained
weight from weeks 0 to 6, but from weeks 6 to 9 there was an
average weight loss of 0.05 kg (Table 1). There was, however, no
statistically significant difference between the treatment groups
and the control group over the 9 weeks period (P = 0.9564 for
pCI-neo_oppA and P = 0.5290 for VR1020_oppA).
The presence of mycoplasma infections was monitored with
PCR during the trial (Table 2). Mycoplasma infections could not
be detected in any of the groups at weeks 0, 3, and 6. Infections
were, however, detected at week 9. At this point the ostriches
had been in Oudtshoorn for 36 days, of which 8 days were out
of quarantine.
In the groups that received the VR1020_oppA vaccine the
highest percentage of infections at week 9 was due to Ms02
(10.5%) followed by Ms03 (5.2%) and Ms01 (3.5%) (Table 2).
Compared to this, the groups that received the pCI-neo_oppA
vaccine had fewer mycoplasma infections. Amongst these the
highest percentage of infections was again due to Ms02 (7.2%)
followed by Ms03 (3.6%) and Ms01 (1.8%). For both vaccine
groups, some of the birds were infected bymore than one of these
Mycoplasma species. The only group that had no PCR-detectable
mycoplasma infections at week 9 was the group that had received
1,200 µg of the VR1020_oppA vaccine and the control group.
DISCUSSION
In this study, DNA vaccines were developed for ostriches using
the oppA gene of an ostrich-infecting mycoplasma (Ms03) as
vaccine antigen. The expression vectors used (pCI-neo and
VR1020), were selected based on DNA vaccine studies in other
FIGURE 1 | Expression of recombinant GST-OppA protein. (A) SDS-PAGE analysis of the expressed OppA protein and (B) western blot analysis using anti-GST
antibody. Lane 1 E. coli BL21(DE3)pLysS cells expressing GST-control, lane 2 E. coli BL21(DE3)pLysS cells expressing GST-OppA protein, and lane 3 isolated
recombinant GST-OppA protein. MM is the GE Healthcare full-range rainbow molecular weight marker, molecular sizes indicated in kDa.
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FIGURE 2 | Anti-OppA antibody response elicited in response to vaccination
with different doses of the pCI-neo_oppA (A) and VR1020_oppA (B) vaccines.
The black arrows indicate the time points at which the ostriches were
vaccinated. The control group did not receive any vaccine.
birds, and on their immunostimulatory characteristics (45–
47). After vaccination of ±3-month-old chicks a statistically
significant anti-OppA antibody response could not be detected at
week 3, although a general trend of increases in the average titer
values was observed from week 0 to 3 for groups that received
the VR1020_oppA vaccines. Based on previous studies using
inactivated vaccines in ostriches (42, 48), we expected a primary
immune response about 3 weeks after the first vaccination (i.e.,
between weeks 0 and 6).
After administering a booster vaccination, both DNA vaccines
were able to elicit a statistically significant anti-OppA antibody
response. As these responses against OppA were significant
in comparison to the negative responses following the first
TABLE 1 | The average weight gain of ostriches measured during the course of
the trial.
Group Dose Group size* Average weight (kg)
Week 0 Week 3# Week 6 Week 9
pCI-neo_oppA 100 µg 19 26.5 No weight
recorded
43.2 44.9
600 µg 17 26.0 42.7 43.7
1,200 µg 19 26.8 45.8 45.4
VR1020_oppA 100 µg 19 27.5 47.9 47.2
600 µg 18 26.2 42.7 41.1
1,200 µg 19 26.0 44.5 42.9
Control – 17 27.2 44.2 43.8
*At the start of the trial there was 20 ostriches in each group, during the trial some of
the ostriches lost their tags and were excluded from the analysis. #No scale available to
record weight.
vaccinations, this is evidence of a secondary immune response as
a result of immune memory. If memory cells are produced after
the initial contact with an antigen, subsequent exposure to the
same antigen will allow the host to recognize the antigen faster,
and with greater magnitude (49, 50).
The responses elicited by the DNA vaccines were, however,
dose dependent as well as vector dependent since different
results were produced by each vaccine when using the same
dose. This highlights a possible role of the vaccine vector in
the observed antibody responses. The VR1020_oppA vaccine,
on average, elicited higher titer values compared to the pCI-
neo_oppA vaccine, which might be due to the TPA signal
sequence of the VR1020 plasmid, which is situated upstream of
the oppA gene, and assists with protein expression in mammalian
cells and export of the protein out of the cell. This would
in turn increase the immunogenicity of the antigen (45). In
addition to this, sequences in the plasmid backbone have intrinsic
immunostimulatory activity which enhance the immune system’s
response to the expressed protein antigen (51, 52).
Over the whole vaccination trial, the health of the ostriches
was monitored by recording weight gain. All groups gained
weight up to week 6, but toward week 9 their weight gain
decreased. Given that this trend was also observed for the
control group ostriches, the weight loss cannot be ascribed to
vaccination. The decrease in weight did, however, coincide with
the movement of the birds to a new location. Ostriches are
known to be severely affected by stress and during this period of
adapting to changes in social dynamic and housing environment,
reduction in weight gain and even weight loss is normal amongst
farmed ostriches (4).
The presence of existing mycoplasma infections at the
start of the trial, as well as changes in infection status
during the trial, were also monitored by PCR analysis of
trachea swabs. Mycoplasma infections could only be detected
at week 9, which was after they were moved and exposed
to the farm environment in Oudtshoorn for more than 30
days. The absence of detectable mycoplasma infections at
the earlier time points may be ascribed to Fraserburg being
outside of the commercial ostrich production region. The
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TABLE 2 | Summary of mycoplasma infections detected during the vaccine trial using PCR.
Vaccine Ms01 Ms02 Ms03
Dose
Week
0 3 6 9 0 3 6 9 0 3 6 9
pCI-neo_oppA 100 µg – – – 1/19 (5.3%) – – – 2/19 (10.5%) – – – 1/19 (5.3%)
600 µg – – – – – – – 1/17 (5.9%) – – – –
1,200 µg – – – – – – – 1/19 (5.3%) – – – 1/19 (5.3%)
Total – – – 1/55 (1.8%) – – – 4/55 (7.2%) – – – 2/55 (3.6%)
VR1020_oppA 100 µg – – – – – – – 2/19 (10.5%) – – – 1/19 (5.3%)
600 µg – – – 2/18 (11.1%) – – – 4/18 (22.2%) – – – 2/18 (11.1%)
1,200 µg – – – – – – – – – – – –
Total – – – 2/57 (3.5%) – – – 6/57 (10.5%) – – – 3/57 (5.2%)
Control – – – – – – – – – – – –
Oudtshoorn district, on the other hand, has a higher incidence
of mycoplasma infections especially during seasonal changes
and our trial was conducted during late autumn. Amongst the
vaccinated groups, the number of detected Ms03 and Ms01
infections were low compared to Ms02, with only the 1200 µg
VR1020_oppA and control group having no detectable ostrich-
infecting mycoplasmas. In future trials, careful consideration
should be given to the timing of the primary and booster
vaccination relative to the time of introduction to grow-
out conditions.
It is possible that the mycoplasma infections had an influence
on the observed antibody responses. In a study done by Yang et al.
(26) using recombinant OppA protein as subunit vaccine against
M. catarrhalis in mice, it was found that the ELISA titer values
were already raised at the start of the vaccination trial which they
ascribed to the presence of existing systemic antibodies to OppA
as a result of existing infections. Despite the possible presence of
antibodies due to mycoplasma infections, this did not mask the
detection of a dose dependent antibody response to the OppA
protein of Ms03 during vaccination.
In conclusion, this is the first study to show that DNA
vaccines are able to elicit an antibody response in ostriches
against a mycoplasma antigen in spite of ostriches being
prone to environmentally induced stress conditions that can
suppress immune function. The mycoplasma OppA protein
was sufficiently immunogenic to induce an anti-OppA antibody
response and this response was firstly, dose dependent and
secondly, required a booster vaccination. Further trials are
required to determine the extent of protection provided by this
mycoplasma antigen relative to the timing of the primary and
booster vaccination before introduction to grow-out conditions.
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